Class-action lawsuits are underway against Hims & Hers Health Inc., representing investors who bought or acquired company securities between April 29, 2025, and June 23, 2025. The lawsuit alleges that ...

Hims & Hers Health, Inc. (NYSE: HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

As we all grow older, it’s understood that our boyish good looks fall wayside—no amount of botox, hair retention, or ...

Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...